Brokerages Set Certara, Inc. (NASDAQ:CERT) PT at $8.85

Certara, Inc. (NASDAQ:CERT) has received an average rating of “Hold” from the thirteen analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $8.85.

Several research analysts have weighed in on the company. Stephens dropped their price target on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Certara in a research note on Friday, May 29th. Robert W. Baird dropped their price target on Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, May 12th. Leerink Partners restated an “outperform” rating and issued a $10.00 price target on shares of Certara in a research note on Thursday, February 26th. Finally, KeyCorp dropped their price target on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Monday, April 13th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Dixon Mitchell Investment Counsel Inc. bought a new stake in shares of Certara in the 3rd quarter worth about $10,587,000. Fort Washington Investment Advisors Inc. OH lifted its holdings in shares of Certara by 133.4% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,272,823 shares of the company’s stock worth $20,024,000 after acquiring an additional 1,299,109 shares during the last quarter. Kopion Asset Management LLC lifted its holdings in shares of Certara by 49.9% in the 4th quarter. Kopion Asset Management LLC now owns 982,710 shares of the company’s stock worth $8,658,000 after acquiring an additional 327,064 shares during the last quarter. Topline Capital Management LLC bought a new stake in shares of Certara in the 3rd quarter worth about $6,678,000. Finally, Brown Brothers Harriman & Co. lifted its holdings in shares of Certara by 34.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,764,034 shares of the company’s stock worth $45,996,000 after acquiring an additional 972,669 shares during the last quarter. 73.96% of the stock is currently owned by institutional investors.

Certara Trading Up 1.1%

CERT stock opened at $5.40 on Wednesday. Certara has a 1-year low of $4.45 and a 1-year high of $13.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. The company has a market capitalization of $840.08 million, a price-to-earnings ratio of -54.00 and a beta of 1.49. The business has a 50 day simple moving average of $5.60 and a two-hundred day simple moving average of $7.00.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business had revenue of $106.92 million during the quarter, compared to the consensus estimate of $106.13 million. During the same quarter in the previous year, the company earned $0.14 earnings per share. The company’s revenue for the quarter was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Research analysts anticipate that Certara will post 0.24 EPS for the current fiscal year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.